These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 33068701)

  • 1. Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-X
    Oh Y; Jung HR; Min S; Kang J; Jang D; Shin S; Kim J; Lee SE; Sung CO; Lee WS; Lee C; Jeong EM; Cho SY
    Cancer Lett; 2021 Jan; 497():123-136. PubMed ID: 33068701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
    Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH
    BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.
    Faber AC; Coffee EM; Costa C; Dastur A; Ebi H; Hata AN; Yeo AT; Edelman EJ; Song Y; Tam AT; Boisvert JL; Milano RJ; Roper J; Kodack DP; Jain RK; Corcoran RB; Rivera MN; Ramaswamy S; Hung KE; Benes CH; Engelman JA
    Cancer Discov; 2014 Jan; 4(1):42-52. PubMed ID: 24163374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.
    Okamoto K; Zaanan A; Kawakami H; Huang S; Sinicrope FA
    Mol Cancer Res; 2015 Apr; 13(4):659-69. PubMed ID: 25548100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models.
    Corcoran RB; Cheng KA; Hata AN; Faber AC; Ebi H; Coffee EM; Greninger P; Brown RD; Godfrey JT; Cohoon TJ; Song Y; Lifshits E; Hung KE; Shioda T; Dias-Santagata D; Singh A; Settleman J; Benes CH; Mino-Kenudson M; Wong KK; Engelman JA
    Cancer Cell; 2013 Jan; 23(1):121-8. PubMed ID: 23245996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low‑dose trametinib and Bcl‑xL antagonist have a specific antitumor effect in KRAS‑mutated colorectal cancer cells.
    Koyama M; Kitazawa M; Nakamura S; Matsumura T; Miyazaki S; Miyagawa Y; Muranaka F; Tokumaru S; Okumura M; Yamamoto Y; Ehara T; Hondo N; Takahata S; Takeoka M; Miyagawa SI; Soejima Y
    Int J Oncol; 2020 Nov; 57(5):1179-1191. PubMed ID: 32901840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Combination Treatment Targeting BCL-X
    Cho SY; Han JY; Na D; Kang W; Lee A; Kim J; Lee J; Min S; Kang J; Chae J; Kim JI; Park H; Lee WS; Lee C
    Mol Cancer Ther; 2017 Oct; 16(10):2178-2190. PubMed ID: 28611106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in
    Nangia V; Siddiqui FM; Caenepeel S; Timonina D; Bilton SJ; Phan N; Gomez-Caraballo M; Archibald HL; Li C; Fraser C; Rigas D; Vajda K; Ferris LA; Lanuti M; Wright CD; Raskin KA; Cahill DP; Shin JH; Keyes C; Sequist LV; Piotrowska Z; Farago AF; Azzoli CG; Gainor JF; Sarosiek KA; Brown SP; Coxon A; Benes CH; Hughes PE; Hata AN
    Cancer Discov; 2018 Dec; 8(12):1598-1613. PubMed ID: 30254092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells.
    Li X; Li B; Ni Z; Zhou P; Wang B; He J; Xiong H; Yang F; Wu Y; Lyu X; Zhang Y; Zeng Y; Lian J; He F
    Mol Cancer Ther; 2017 Sep; 16(9):1806-1818. PubMed ID: 28533436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of NANOG/NANOGP8 downregulates MCL-1 in colorectal cancer cells and enhances the therapeutic efficacy of BH3 mimetics.
    Mattoo AR; Zhang J; Espinoza LA; Jessup JM
    Clin Cancer Res; 2014 Nov; 20(21):5446-55. PubMed ID: 25208882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21((CIP1/WAF1)) in human cancer cells.
    Li J; Chen Y; Wan J; Liu X; Yu C; Li W
    Br J Pharmacol; 2014 Jul; 171(13):3182-95. PubMed ID: 24571452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic anti-proliferative effects of combination of ABT-263 and MCL-1 selective inhibitor A-1210477 on cervical cancer cell lines.
    Lian BSX; Yek AEH; Shuvas H; Abdul Rahman SF; Muniandy K; Mohana-Kumaran N
    BMC Res Notes; 2018 Mar; 11(1):197. PubMed ID: 29580266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia.
    Wang X; Mak PY; Mu H; Tao W; Rao A; Visweswaran R; Ruvolo V; Pachter JA; Weaver DT; Andreeff M; Xu B; Carter BZ
    Mol Cancer Ther; 2020 Aug; 19(8):1636-1648. PubMed ID: 32404407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism.
    Zaanan A; Okamoto K; Kawakami H; Khazaie K; Huang S; Sinicrope FA
    J Biol Chem; 2015 Sep; 290(39):23838-49. PubMed ID: 26245900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems.
    Shang E; Zhang Y; Shu C; Ishida CT; Bianchetti E; Westhoff MA; Karpel-Massler G; Siegelin MD
    Sci Rep; 2018 Oct; 8(1):15383. PubMed ID: 30337641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer.
    Pek M; Yatim SMJM; Chen Y; Li J; Gong M; Jiang X; Zhang F; Zheng J; Wu X; Yu Q
    Oncogene; 2017 Aug; 36(35):4975-4986. PubMed ID: 28459468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BH3 Mimetic Sensitivity of Colorectal Cancer Cell Lines in Correlation with Molecular Features Identifies Predictors of Response.
    Zhang L; Ramesh P; Steinmetz M; Medema JP
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR screens identify a novel combination treatment targeting BCL-X
    Jung HR; Oh Y; Na D; Min S; Kang J; Jang D; Shin S; Kim J; Lee SE; Jeong EM; An JY; Sung CO; Lee WS; Lee C; Cho SY
    Oncogene; 2021 May; 40(18):3287-3302. PubMed ID: 33846570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracellular levels of reactive oxygen species correlate with ABT-263 sensitivity in non-small-cell lung cancer cells.
    Ohgino K; Terai H; Yasuda H; Nukaga S; Hamamoto J; Tani T; Kuroda A; Arai D; Ishioka K; Masuzawa K; Ikemura S; Kawada I; Naoki K; Fukunaga K; Soejima K
    Cancer Sci; 2020 Oct; 111(10):3793-3801. PubMed ID: 32687646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.